- Home
- GMAB vs ITT Comparison
GMAB vs ITT Comparison
Compare GMAB & ITT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- ITT
- Stock Information
- Founded
- GMAB 1999
- ITT 1920
- Country
- GMAB Denmark
- ITT United States
- Employees
- GMAB 2638
- ITT N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- ITT Fluid Controls
- Sector
- GMAB Health Care
- ITT Industrials
- Exchange
- GMAB Nasdaq
- ITT Nasdaq
- Market Cap
- GMAB 13.4B
- ITT 11.8B
- IPO Year
- GMAB N/A
- ITT N/A
- Fundamental
- Price
- GMAB $22.25
- ITT $151.94
- Analyst Decision
- GMAB Buy
- ITT Strong Buy
- Analyst Count
- GMAB 9
- ITT 9
- Target Price
- GMAB $39.17
- ITT $165.50
- AVG Volume (30 Days)
- GMAB 1.3M
- ITT 421.9K
- Earning Date
- GMAB 05-08-2025
- ITT 07-31-2025
- Dividend Yield
- GMAB N/A
- ITT 0.92%
- EPS Growth
- GMAB 276.80
- ITT 22.94
- EPS
- GMAB 18.36
- ITT 6.28
- Revenue
- GMAB $3,230,902,140.00
- ITT $3,633,100,000.00
- Revenue This Year
- GMAB $747.74
- ITT $5.13
- Revenue Next Year
- GMAB $14.81
- ITT $4.64
- P/E Ratio
- GMAB $1.21
- ITT $24.40
- Revenue Growth
- GMAB 25.43
- ITT 6.99
- 52 Week Low
- GMAB $17.24
- ITT $105.64
- 52 Week High
- GMAB $28.56
- ITT $161.13
- Technical
- Relative Strength Index (RSI)
- GMAB 64.68
- ITT 62.05
- Support Level
- GMAB $20.88
- ITT $149.47
- Resistance Level
- GMAB $22.15
- ITT $152.01
- Average True Range (ATR)
- GMAB 0.39
- ITT 2.33
- MACD
- GMAB 0.14
- ITT -0.52
- Stochastic Oscillator
- GMAB 94.62
- ITT 73.31
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About ITT ITT Inc.
ITT began its journey as International Telephone & Telegraph in 1920. Through decades of acquisitions in the mid-1900s, ITT went from manufacturing telephone switching equipment to operating hotels, car rentals, insurance agencies, and bread bakeries. In 1995, the firm split into three separate entities, one of which is the ITT in current operation. After a few more spinoffs in 2011, today ITT Inc. sells automotive, industrial, and aerospace products such as brake pads, seals, pumps, valves, connectors, and regulators. It has operations around the globe with notable exposures to North America, Europe, and Asia.